{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:59:13Z","timestamp":1787061553759,"version":"build-2736575974"},"reference-count":18,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T00:00:00Z","timestamp":1640822400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Current Oncology"],"abstract":"<jats:p>It has been reported that 5.1\u20137.0% of acute pericarditis are carcinomatous pericarditis. Malignant pericardial effusion (MPE) can progress to cardiac tamponade, which is a life-threatening condition. The effectiveness and feasibility of intrapericardial instillation of carboplatin (CBDCA; 150 mg\/body) have never been evaluated in patients with lung cancer, which is the most common cause of MPE. Therefore, we evaluated the effectiveness and feasibility of intrapericardial administration of CBDCA following catheter drainage in patients with lung cancer-associated MPE. In this retrospective study, 21 patients with symptomatic lung cancer-associated MPE, who were administered intrapericardial CBDCA (150 mg\/body) at Gunma Prefectural Cancer Center between January 2005 and March 2018, were included. The patients\u2019 characteristics, response to treatment, and toxicity incidence were evaluated. Thirty days after the intrapericardial administration of CBDCA, MPE was controlled in 66.7% of the cases. The median survival period from the day of administration until death or last follow-up was 71 days (range: 10\u20132435 days). Grade 1\u20132 pain, nausea, fever, and neutropenia were noted after intrapericardial CBDCA administration. No treatment-related deaths were noted in the current study. Intrapericardial administration of CBDCA (150 mg\/body) did not cause serious toxicity, and patients exhibited promising responses to lung cancer-associated MPE. Prospective studies using larger sample sizes are needed to explore the efficacy and safety of this treatment for managing lung cancer-associated MPE.<\/jats:p>","DOI":"10.3390\/curroncol29010015","type":"journal-article","created":{"date-parts":[[2021,12,30]],"date-time":"2021-12-30T21:41:21Z","timestamp":1640900481000},"page":"163-172","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Management of Lung Cancer-Associated Malignant Pericardial Effusion with Intrapericardial Administration of Carboplatin: A Retrospective Study"],"prefix":"10.3390","volume":"29","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3097-4255","authenticated-orcid":false,"given":"Hisao","family":"Imai","sequence":"first","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Japan"},{"name":"Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-0495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5548-7686","authenticated-orcid":false,"given":"Kyoichi","family":"Kaira","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka 350-0495, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken","family":"Masubuchi","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Koichi","family":"Minato","sequence":"additional","affiliation":[{"name":"Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota 373-8550, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,12,30]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"2739","DOI":"10.1161\/CIRCULATIONAHA.106.662114","article-title":"Indicators of poor prognosis of acute pericarditis","volume":"115","author":"Imazio","year":"2007","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1001\/jama.1987.03390080078037","article-title":"Management of malignant pericardial effusion and tamponade","volume":"257","author":"Press","year":"1987","journal-title":"JAMA"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1056\/NEJMra022643","article-title":"Acute cardiac tamponade","volume":"349","author":"Spodick","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics 2021","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_5","first-page":"195","article-title":"Neoplasms metastatic to the heart: Review of 3314 consecutive autopsies","volume":"3","author":"Abraham","year":"1990","journal-title":"Am. J. Cardiovasc. Pathol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1002\/1097-0142(19930101)71:1<93::AID-CNCR2820710115>3.0.CO;2-R","article-title":"Cardiac tamponade caused by primary lung cancer and the management of pericardial effusion","volume":"71","author":"Okamoto","year":"1993","journal-title":"Cancer"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1200\/JCO.2005.00.745","article-title":"Abnormal cytology predicts poor prognosis in cancer patients with pericardial effusion","volume":"23","author":"Gornik","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/sj.bjc.6604866","article-title":"A randomised trial of intrapericardial bleomycin for malignant pericardial effusion with lung cancer (JCOG9811)","volume":"100","author":"Kunitoh","year":"2009","journal-title":"Br. J. Cancer"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/JTO.0b013e31802c8260","article-title":"Catheter drainage followed by the instillation of bleomycin to manage malignant pericardial effusion in non-small cell lung cancer: A multi-institutional phase II trial","volume":"2","author":"Maruyama","year":"2007","journal-title":"J. Thorac. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/jjco\/hyi019","article-title":"Management of malignant pericardial effusion with instillation of mitomycin C in non-small cell lung cancer","volume":"35","author":"Kaira","year":"2005","journal-title":"Jpn. J. Clin. Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.2000.1397","article-title":"Controlling malignant pericardial effusion by intrapericardial carboplatin administration in patients with primary non-small-cell lung cancer","volume":"83","author":"Moriya","year":"2000","journal-title":"Br. J. Cancer"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1007\/s00280-019-03897-0","article-title":"Intrapericardial carboplatin in the management of malignant pericardial effusion in breast cancer: A pilot study","volume":"84","author":"Kotake","year":"2019","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_13","first-page":"1903","article-title":"Intracavitary bleomycin in the management of malignant effusions: A multicenter study","volume":"66","author":"Ostrowski","year":"1982","journal-title":"Cancer Treat. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/icvts\/ivu267","article-title":"Palliative treatment for symptomatic malignant pericardial effusion","volume":"19","author":"Jama","year":"2014","journal-title":"Interact. Cardiovasc. Thorac. Surg."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/0002-9149(87)90411-5","article-title":"Medical management of malignant pericardial effusion by tetracycline sclerosis","volume":"60","author":"Shepherd","year":"1987","journal-title":"Am. J. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1053\/euhj.2002.3328","article-title":"Moll R: Neoplastic pericardial effusion. Efficacy and safety of intrapericardial treatment with cisplatin","volume":"23","author":"Maisch","year":"2002","journal-title":"Eur. Heart J."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1378\/chest.126.5.1412","article-title":"Long-term results of intrapericardial chemotherapeutic treatment of malignant pericardial effusions with thiotepa","volume":"126","author":"Martinoni","year":"2004","journal-title":"Chest"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1200\/JCO.1998.16.7.2371","article-title":"Intracavitary chemotherapy with thiotepa in malignant pericardial effusions: An active and well-tolerated regimen","volume":"16","author":"Colleoni","year":"1998","journal-title":"J. Clin. Oncol."}],"container-title":["Current Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/1\/15\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T07:56:13Z","timestamp":1760169373000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1718-7729\/29\/1\/15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12,30]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,1]]}},"alternative-id":["curroncol29010015"],"URL":"https:\/\/doi.org\/10.3390\/curroncol29010015","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-558833\/v1","asserted-by":"object"}]},"ISSN":["1718-7729"],"issn-type":[{"value":"1718-7729","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12,30]]}}}